Antibiotic joins fight against aggressive breast cancer in major trial
NCT ID NCT04722978
Summary
This study is testing if adding the antibiotic moxifloxacin to standard first-line chemotherapy helps people with metastatic triple-negative breast cancer live longer without their cancer getting worse. It will involve about 228 participants across multiple centers. Patients will be randomly assigned to receive either the real antibiotic or a placebo pill alongside their chemotherapy, and neither they nor their doctors will know which one they are getting.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.